Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence ...

This post was updated March 31 at 11:21 p.m. UCLA researchers developed a human stem cell-derived cell therapy for an ...

Researchers at UCLA have developed a powerful new weapon in the battle against kidney cancer. Instead of relying on treatments tailored to each patient, this innovation uses specially engineered ...

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival rates have steadily declined over the last few decades. The most ...

GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that the European Patent Office has ...

Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and immunoediting compared with single-pathway CAR-T constructs. Complete tumor ...

Phase I clinical trials, using αGalCer-loaded DCs to target iNKT cells, have shown promise in treating some patients with cancer. As humans have a low frequency of iNKT cells, therapies that combine ...

PALO ALTO, Calif., Jan. 30, 2026 /PRNewswire/ -- Leading GMP cell therapy CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells ...

Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful ...

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to treat multiple solid tumors. The study focused on engineered invariant ...